1
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1
Condition(s): HIV-1; HIV Infections Last Updated: January 31, 2013Completed
102 Clinical Trials for: Integrase Inhibitor, Page 1 of 6
Hide Studies Not Seeking New Volunteers
2
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Condition(s): Infection, Human Immunodeficiency Virus Last Updated: May 9, 2013Active, not recruiting
3
IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients
Condition(s): HIV Infections Last Updated: January 24, 2013Recruiting
4
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
Condition(s): HIV Infections Last Updated: July 18, 2011Terminated
5
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
Condition(s): Infection, Human Immunodeficiency Virus Last Updated: January 21, 2013Active, not recruiting
6
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Condition(s): Infection, Human Immunodeficiency Virus Last Updated: March 28, 2013Active, not recruiting
7
Raltegravir Activity In Lymphoid Tissues
Condition(s): HIV Infection; HIV Infections Last Updated: October 24, 2011Withdrawn
8
The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection
Condition(s): Primary HIV (Acute or Early); Chronic HIV Infection Last Updated: March 31, 2009Active, not recruiting
9
Kaletra in Combination With Antiretroviral Agents
Condition(s): Human Immunodeficiency Virus Last Updated: March 8, 2013Recruiting
10
Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
Condition(s): HIV Infections; HCV Infections Last Updated: July 23, 2012Completed
11
Integrase Inhibitor (MK-0518) Viral Decay
Condition(s): HIV Infections Last Updated: June 4, 2012Completed
12
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
Condition(s): Acquired Immunodeficiency Syndrome; HIV-1 Infection Last Updated: March 31, 2011Completed
13
Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.
Condition(s): HIV; HIV-1; Human Immunodeficiency Virus Last Updated: July 28, 2008Completed
14
Management of HIV-1 Patients Treated With Antiretroviral Combination Therapy Including Raltegravir (MK0518-138)
Condition(s): HIV Infections Last Updated: January 24, 2013Completed
15
Safety of and Immune Response to GSK1349572 in HIV-1 Infected Infants, Children, and Adolescents
Condition(s): HIV Infections Last Updated: March 15, 2013Recruiting
16
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
Condition(s): HIV Last Updated: December 3, 2012Withdrawn
17
Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients
Condition(s): HIV Infections Last Updated: June 23, 2005Completed
18
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
Condition(s): HIV Infections Last Updated: May 31, 2012Completed
19
HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy
Condition(s): HIV-1 Infection Last Updated: July 29, 2010Terminated
20
Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
Condition(s): HIV Infections Last Updated: November 7, 2012Completed
